Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
about
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerProlactinoma ErbB receptor expression and targeted therapy for aggressive tumors.Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.The role of HER2 in cancer therapy and targeted drug deliveryTyrosine kinases in inflammatory dermatologic disease.Breast cancer genomes--form and functionComputational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.Biomarkers of response and resistance to antiangiogenic therapy.ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic miceBrain tissue energy dependence of CaM kinase IV cascade activation during hypoxia in the cerebral cortex of newborn pigletsDynamics of DNA damage induced pathways to cancerSimultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-MethylselenocysteineAnti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and AlternativeHER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeuticsDevelopment of high-throughput quantitative assays for glucose uptake in cancer cell lines.The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cellsThe anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.Therapeutic implications of the cancer stem cell hypothesis.Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.New targeted therapies for gastric cancer.Novel approaches to treating leptomeningeal metastases.Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB.Catalytic mechanisms and regulation of protein kinases.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Mechanistic insights into the activation of oncogenic forms of EGF receptor.Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.In vivo near-infrared imaging of ErbB2 expressing breast tumors with dual-axes confocal endomicroscopy using a targeted peptide.Mechanism of CaM kinase IV activation during hypoxia in neuronal nuclei of the cerebral cortex of newborn piglets: the role of Src kinase.Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.Shared molecular targets in pediatric gliomas and ependymomas.
P2860
Q28072513-D4D243CB-04C4-483E-9CD7-BD659F1751C9Q33680681-29AB48DE-08AE-4F75-9059-13D2C17E8C35Q33810494-7DD51A1F-85DC-4204-8215-AC586E8F425AQ34054213-C3EC90C0-390A-42C2-B262-5A0C56A58413Q34166503-1CCE9DD6-A2FC-4B5B-AFE4-7651244F2FA2Q34207688-DCBCDA54-312B-4B06-B6F4-9512216D916BQ34473476-A6A68306-DD49-45DF-A3E3-AD935A8C9473Q34673567-292ED621-1852-444B-8E62-EF99B2FA263EQ34745279-5674D5FF-470F-4328-A605-BF3031F8810AQ34775809-323E4CF4-0714-4563-A346-0208CB941AC6Q34983908-C5D97DB9-5059-4299-B2F6-317793F498FDQ35222776-EDF72E73-5632-4751-9FEC-50FCA50252EDQ35237773-C4260D21-0068-4F41-9B63-B471A2AE3C1FQ35892045-3A2F4299-6AD6-4A89-8DBA-FA09DA0F6B9FQ36004109-FF1F0076-A48C-4F78-9F20-E7124AD93F17Q36396421-E464731A-0182-4879-B8E1-7951A5E46796Q36768688-29F98CB4-F7D3-41A3-B897-333FCD6BEA86Q36771985-940AAF4E-9EAF-4891-983E-AF314EA4833AQ37312071-909EAB72-9BF8-4C01-A24E-1C4DBADA1EC3Q37361549-67D4ACC1-80FA-4CAC-8125-04B67A024F05Q37403285-1CA88C4B-37D1-44DA-A5BA-296CB2BDA7C0Q37459640-5F9B0F60-C832-4C2F-9AE8-E63CFF659AF5Q37582080-D1B8443E-DB8D-420D-BECA-9447D26C7F75Q37853198-CBBBAA6B-AEC3-471C-B034-39DCCAB53ECBQ37923386-F99AB103-314F-48C5-BFC9-FC3F8D6A4020Q37938692-344ED34A-2FB5-47A7-AD93-3F4FDD177CDEQ38268502-D88BF2A5-592B-4546-9398-0E6CFE3349B2Q38812867-DA02A333-5C73-4981-A64B-AAF89965E523Q39603355-B89108EB-7D3B-441B-8709-8E96D7C9135AQ39633289-D10EAE0D-527D-438F-956E-51A9AC07EE82Q39800101-3290A3B3-78E3-4662-9A1C-498990F1A534Q47123343-1992D702-7E49-49A0-99FB-D2DD55444356Q53252188-E7187BDD-544F-4A02-88E7-B89F7781D985Q54599560-8480E61B-9186-45D8-89E0-B656DEF73B45Q55054249-C19048E4-9EE1-460C-99CB-4BF65F6C171AQ55463435-7961C1DD-19A8-4859-84B5-CFB2C55C1A38
P2860
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug Insight: intracellular in ...... of lapatinib in breast cancer.
@en
Drug Insight: intracellular in ...... of lapatinib in breast cancer.
@nl
type
label
Drug Insight: intracellular in ...... of lapatinib in breast cancer.
@en
Drug Insight: intracellular in ...... of lapatinib in breast cancer.
@nl
prefLabel
Drug Insight: intracellular in ...... of lapatinib in breast cancer.
@en
Drug Insight: intracellular in ...... of lapatinib in breast cancer.
@nl
P356
P1476
Drug Insight: intracellular in ...... of lapatinib in breast cancer.
@en
P2093
David A Cameron
Steven Stein
P304
P356
10.1038/NCPONC1156
P577
2008-07-01T00:00:00Z